GlassScriptPhysician profile
Melissa K Levin
NPI 1831488014
$223,853.17
in general payments reported to CMS, 2019-2025
32 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $29K · 2021: $46K · 2022: $27K · 2023: $27K · 2024: $12K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $10K · Travel and Lodging: $3,118 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,062.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,850.00 |
| Food and Beverage | $10,281.24 |
| Travel and Lodging | $3,117.64 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $90,488.59 | 2019-2022 | |
| Merz North America, INC. | $61,414.67 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $51,890.83 | 2019-2025 | Aklief, Epsolay, Oracea |
| Abbvie INC. | $10,199.35 | 2020-2024 | |
| Revance Therapeutics, INC. | $7,348.94 | 2024-2025 | Daxxify, Daxi |
| Leo Pharma INC. | $310.90 | 2019-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $232.28 | 2019-2024 | Dupixent |
| Mayne Pharma Commercial LLC | $227.07 | 2019-2021 | |
| Celgene Corporation | $184.48 | 2019 | |
| Vyne Pharmaceuticals INC. | $165.11 | 2020-2021 | |
| Journey Medical Corporation | $148.11 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $136.78 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.26 | 2019-2021 | |
| Pfizer INC. | $128.74 | 2019-2021 | |
| Almirall LLC | $111.87 | 2020-2024 | Seysara |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $111.75 | 2021-2025 | |
| Lilly USA, LLC | $104.45 | 2021 | |
| Dermavant Sciences, INC. | $63.59 | 2023 | Vtama |
| Janssen Biotech, INC. | $53.30 | 2021 | |
| Epi Health, LLC | $49.72 | 2021 | |
| Amgen INC. | $44.52 | 2020-2024 | Otezla |
| Incyte Corporation | $44.35 | 2021 | |
| Biofrontera INC. | $42.90 | 2021 | |
| Ucb, INC. | $40.57 | 2021 | |
| Dermira, INC. | $29.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.71 | 2024 | |
| Aclaris Therapeutics, INC. | $23.54 | 2019 | |
| Arcutis Biotherapeutics, INC. | $23.45 | 2025 | Zoryve |
| Stemline Therapeutics INC. | $21.65 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $19.28 | 2019 | |
| Medline Industries LP | $17.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.